|
1
|
Liu M, Jiang L and Guan XY: The genetic
and epigenetic alterations in human hepatocellular carcinoma: A
recent update. Protein Cell. 5:673–691. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pang R and Poon RT: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folkman J: Fundamental concepts of the
angiogenic process. Curr Mol Med. 3:643–651. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao J, Lin W, Cao Z, Zhuang Q, Zheng L,
Peng J and Hong Z: Total alkaloids of Rubus alceifolius Poir
inhibit tumor angiogenesis through suppression of the Notch
signaling pathway in a mouse model of hepatocellular carcinoma. Mol
Med Rep. 11:357–361. 2015.
|
|
8
|
Casazza A, Laoui D, Wenes M, Rizzolio S,
Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA,
Tamagnone L and Mazzone M: Impeding macrophage entry into hypoxic
tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis
and restores antitumor immunity. Cancer Cell. 24:695–709. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee E, Koskimaki JE, Pandey NB and Popel
AS: Inhibition of lymphangiogenesis and angiogenesis in breast
tumor xenografts and lymph nodes by a peptide derived from
transmembrane protein 45A. Neoplasia. 15:112–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Konkimalla VB and Efferth T:
Evidence-based Chinese medicine for cancer therapy. J
Ethnopharmacol. 116:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen
M and Wang Y: Chinese herbal medicine-derived compounds for cancer
therapy: A focus on hepatocellular carcinoma. J Ethnopharmacol.
149:601–612. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han SY and Li PP: Progress of research in
antitumor mechanisms with Chinese medicine. Chin J Integr Med.
15:316–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li
D, Wu Y, Song Y, Luo J, Pang X, et al: Cucurbitacin E, a
tetracyclic triterpenes compound from Chinese medicine, inhibits
tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling
pathway. Carcinogenesis. 31:2097–2104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang XY, Wang L, Huang ZL, Zheng Q, Li QS
and Tang ZY: Herbal extract 'Songyou Yin' inhibits tumor growth and
prolongs survival in nude mice bearing human hepatocellular
carcinoma xenograft with high metastatic potential. J Cancer Res
Clin Oncol. 135:1245–1255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao LD, Wang JH, Jin GR, Zhao Y and Zhang
HJ: Neuroprotective effect of Buyang Huanwu decoction against focal
cerebral ischemia/reperfusion injury in rats-time window and
mechanism. J Ethnopharmacol. 140:339–344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai G, Liu B, Liu W, Tan X, Rong J, Chen
X, Tong L and Shen J: Buyang Huanwu decoction can improve recovery
of neurological function, reduce infarction volume, stimulate
neural proliferation and modulate VEGF and Flk1 expressions in
transient focal cerebral ischaemic rat brains. J Ethnopharmacol.
113:292–299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shang B, Cao Z and Zhou Q: Progress in
tumor vascular normalization for anticancer therapy: Challenges and
perspectives. Front Med. 6:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye
QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on
metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
130:187–196. 2004. View Article : Google Scholar
|
|
20
|
Xu JQ: Formulas of Chinese Medicine.
Shanghai Scientific & Technical Publishers; Shanghai: pp.
1–298. 1985
|
|
21
|
Chinese Pharmacopoeia Commission: Chinese
pharmacopoeia. Chemical Industry Press; Beijing China: pp.
5472005
|
|
22
|
Kang M, Ou H, Wang R, Liu W, Mao Y and
Tang A: Effect of trichosanthin on apoptosis and telomerase
activity of nasopharyngeal carcinomas in nude mice. J BUON.
18:675–682. 2013.PubMed/NCBI
|
|
23
|
Institute of Laboratory Animal Resources
(US): Committee on Care, Use of Laboratory Animals, and National
Institutes of Health (US). Division of Research Resources: Guide
for the care and use of laboratory animals. 1st edition. National
Academies Press; Washington, DC: 1996
|
|
24
|
Li Y, Tang Z, Ye L, Liu B, Liu K, Chen J
and Xue Q: Establishment of a hepatocellular carcinoma cell line
with unique metastatic characteristics through in vivo selection
and screening for metastasis-related genes through cDNA microarray.
J Cancer Res Clin Oncol. 129:43–51. 2003.PubMed/NCBI
|
|
25
|
Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L,
Qin LX, Wu WZ, Liu YK, Ye SL and Tang ZY: Overexpression of
platelet-derived growth factor receptor alpha in endothelial cells
of hepatocellular carcinoma associated with high metastatic
potential. Clin Cancer Res. 11:8557–8563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ye QH, Qin LX, Forgues M, He P, Kim JW,
Peng AC, Simon R, Li Y, Robles AI, Chen Y, et al: Predicting
hepatitis B virus-positive metastatic hepatocellular carcinomas
using gene expression profiling and supervised machine learning.
Nat Med. 9:416–423. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis-correlation in invasive breast
carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang ZL, Liu ZS and Sun Q: Effects of
thalidomide on angiogenesis and tumor growth and metastasis of
human hepatocellular carcinoma in nude mice. World J Gastroenterol.
11:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan
ST and Wong J: Tumor microvessel density as a predictor of
recurrence after resection of hepatocellular carcinoma: A
prospective study. J Clin Oncol. 20:1775–1785. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ng IO, Poon RT, Lee JM, Fan ST, Ng M and
Tso WK: Microvessel density, vascular endothelial growth factor and
its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J
Clin Pathol. 116:838–845. 2001. View Article : Google Scholar
|
|
31
|
Yao Y, Kubota T, Takeuchi H and Sato K:
Prognostic significance of microvessel density determined by an
anti-CD105/endoglin monoclonal antibody in astrocytic tumors:
Comparison with an anti-CD31 monoclonal antibody. Neuropathology.
25:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wikström P, Lissbrant IF, Stattin P,
Egevad L and Bergh A: Endoglin (CD105) is expressed on immature
blood vessels and is a marker for survival in prostate cancer.
Prostate. 51:268–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fonsatti E and Maio M: Highlights on
endoglin (CD105): From basic findings towards clinical applications
in human cancer. J Transl Med. 2:182004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Imura S, Miyake H, Izumi K, Tashiro S and
Uehara H: Correlation of vascular endothelial cell proliferation
with microvessel density and expression of vascular endothelial
growth factor and basic fibroblast growth factor in hepatocellular
carcinoma. J Med Invest. 51:202–209. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka F, Otake Y, Yanagihara K, Kawano Y,
Miyahara R, Li M, Yamada T, Hanaoka N, Inui K and Wada H:
Evaluation of angiogenesis in non-small cell lung cancer comparison
between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer
Res. 7:3410–3415. 2001.PubMed/NCBI
|
|
36
|
Stephens TD, Bunde CJ and Fillmore BJ:
Mechanism of action in thalidomide teratogenesis. Biochem
Pharmacol. 59:1489–1499. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang ZL, Liu ZS and Sun Q: Anti-tumor
effect of thalidomide and paclitaxel on hepatocellular carcinoma in
nude mice. Chin Med J (Engl). 118:1688–1694. 2005.
|
|
38
|
Zhou L, Sohet F and Daneman R:
Purification and culture of central nervous system pericytes. Cold
Spring Harb Protoc. 2014:581–583. 2014.PubMed/NCBI
|
|
39
|
Masood R, Cai J, Zheng T, Smith DL, Hinton
DR and Gill PS: Vascular endothelial growth factor (VEGF) is an
autocrine growth factor for VEGF receptor-positive human tumors.
Blood. 98:1904–1913. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hirakawa S, Brown LF, Kodama S, Paavonen
K, Alitalo K and Detmar M: VEGF-C-induced lymphangiogenesis in
sentinel lymph nodes promotes tumor metastasis to distant sites.
Blood. 109:1010–1017. 2007. View Article : Google Scholar
|
|
41
|
Zhang YK, Han XY and Che ZY: Effects of
buyang huanwu tang combined with bone marrow mesenchymal stem cell
transplantation on the expression of VEGF and Ki-67 in the brain
tissue of the cerebral ischemia-reperfusion model rat. J Tradit
Chin Med. 30:278–282. 2010. View Article : Google Scholar
|
|
42
|
Quesada AR, Medina MA and Alba E: Playing
only one instrument may be not enough: Limitations and future of
the antiangiogenic treatment of cancer. Bioessays. 29:1159–1168.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shaheen RM, Tseng WW, Davis DW, Liu W,
Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan
KE, et al: Tyrosine kinase inhibition of multiple angiogenic growth
factor receptors improves survival in mice bearing colon cancer
liver metastases by inhibition of endothelial cell survival
mechanisms. Cancer Res. 61:1464–1468. 2001.PubMed/NCBI
|
|
44
|
Bondjers C, Kalén M, Hellström M, Scheidl
SJ, Abramsson A, Renner O, Lindahl P, Cho H, Kehrl J and Betsholtz
C: Transcription profiling of PDGF-B deficient embryos identifies
RGS5 as a novel marker for pericytes and vascular smooth muscle
cells. Am J Pathol. 162:721–729. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou J, Moroi K, Nishiyama M, Usui H, Seki
N, Ishida J, Fukamizu A and Kimura S: Characterization of RGS5 in
regulation of G protein-coupled receptor signaling. Life Sci.
68:1457–1469. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bahrami AJ, Gunaje JJ, Hayes BJ, Riehle
KJ, Kenerson HL, Yeung RS, Stempien-Otero AS, Campbell JS and
Mahoney WM Jr: Regulator of G-protein signaling-5 is a marker of
hepatic stellate cells and expression mediates response to liver
injury. PLoS One. 9:e1085052014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen X, Higgins J, Cheung ST, Li R, Mason
V, Montgomery K, Fan ST, van de Rijn M and So S: Novel endothelial
cell markers in hepatocellular carcinoma. Mod Pathol. 17:1198–1210.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Berger M, Bergers G, Arnold B, Hämmerling
GJ and Ganss R: Regulator of G-protein signaling-5 induction in
pericytes coincides with active vessel remodeling during
neovascularization. Blood. 105:1094–1101. 2005. View Article : Google Scholar
|
|
49
|
Carmeliet P and Jain RK: Principles and
mechanisms of vessel normalization for cancer and other angiogenic
diseases. Nat Rev Drug Discov. 10:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kaur B, Khwaja FW, Severson EA, Matheny
SL, Brat DJ and Van Meir EG: Hypoxia and the
hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
Neuro Oncol. 7:134–153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Qing G and Simon MC: Hypoxia inducible
factor-2alpha: A critical mediator of aggressive tumor phenotypes.
Curr Opin Genet Dev. 19:60–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wu XZ, Xie GR and Chen D: Hypoxia and
hepatocellular carcinoma: The therapeutic target for hepatocellular
carcinoma. J Gastroen Hepatol. 22:1178–1182. 2007. View Article : Google Scholar
|
|
53
|
Fukumura D and Jain RK: Tumor
microvasculature and micro-environment: Targets for
anti-angiogenesis and normalization. Microvasc Res. 74:72–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
